Gilead’s unique $5.1 billion licensing deal shows the range of IP monetisation options open to biotech sector

New boss explains that the Big Pharma company will seek out “diverse and creative” asset partnerships – rather than large acquisitions – to boost its pipeline


Get unlimited access to all IAM content